Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.04Last Year’s EPS
-1.29Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 17.46%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The call highlighted a strong start to 2025, with significant progress in product launches and clinical trials. However, challenges remain with regulatory hurdles in Europe and ongoing competition from generics, balanced by strong cash reserves and strategic planning.Company Guidance
During the PTC Therapeutics First Quarter 2025 Earnings Conference Call, the company provided updated guidance for the fiscal year 2025, narrowing its full-year revenue expectations to between $650 million and $800 million. In the first quarter, PTC achieved $190 million in total revenue, driven by strong contributions from its Duchenne muscular dystrophy (DMD) franchise, which generated $134 million. Additionally, the company highlighted a robust cash position of over $2 billion, which supports ongoing commercial and R&D activities as PTC moves towards cash flow breakeven. PTC is preparing for the anticipated global launch of SUFIANCE, a treatment for phenylketonuria (PKU), with expected revenue contributions from European markets in 2025. The company is also pursuing regulatory approvals for SUFIANCE in the U.S. and other products like vatiquinone for Friedreich’s ataxia.Strong Start to 2025 with $190 Million Revenue
PTC Therapeutics achieved $190 million of revenue in the first quarter of 2025, with strong contributions from the DMD franchise.
SUFIANCE's Anticipated Global Launch
Positive CHMP opinion on SUFIANCE marketing authorization with an expected broad label for all PKU patients. Preparations for European and U.S. launches are underway, aiming for over $1 billion in revenue.
PTC518 Huntington’s Disease Program Success
The PIVOT HT Phase 2 study met its primary endpoints of blood HTT lowering and safety, with continued trends of dose-dependent favorable clinical effects after 24 months of treatment.
Strong Cash Position
PTC closed the first quarter with over $2 billion in cash, allowing support for all planned commercial and R&D activities without needing additional capital.
Vatiquinone NDA Progress
FDA review of vatiquinone for Friedreich’s ataxia is progressing well, with no plans for an AdCom meeting, indicating confidence in the approval process.
DMD Franchise Revenue Defense
Delivered strong first-quarter revenue of $134 million for the global DMD franchise, demonstrating effective defense strategies despite challenges.
---
PTCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PTCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $36.19 | $40.76 | +12.63% |
| Feb 27, 2025 | $50.57 | $55.26 | +9.27% |
| Nov 07, 2024 | $42.96 | $44.28 | +3.07% |
| Aug 08, 2024 | $32.45 | $31.29 | -3.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PTC Therapeutics (PTCT) report earnings?
PTC Therapeutics (PTCT) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is PTC Therapeutics (PTCT) earnings time?
PTC Therapeutics (PTCT) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTCT EPS forecast?
PTCT EPS forecast for the fiscal quarter 2025 (Q2) is -1.04.
---